secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001562762-23-000378
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q3 revenue +7.2% to $565M; raises FY2023 adjusted EPS guidance to $19.82-$20.02
--------------------------------------------------------------------------------

- GAAP diluted EPS $4.93 (+30.4% YoY); adjusted diluted EPS $5.32 (+24.9%).
- VITAS net patient revenue $334M (+12.5%), ADC 18,859 (+9.4%), adjusted EBITDA margin 16.5% (+441 bps).
- Roto-Rooter revenue $231M (+0.4%), adjusted EBITDA $66.9M (-3.7%), margin 29.0% (-124 bps).
- Full-year adjusted EPS guidance raised to $19.82-$20.02 from $18.72-$18.92, includes $1.18/sh retention costs.
- Ended quarter with $173M cash, no debt; repurchased $14.3M in shares at avg $504.07.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/che-20230930x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-23-000378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer